

Publication

Sino-EU PerMed Policy Brief on ethical, legal and social aspects

The Sino-EU PerMed project published its 2nd policy brief on ethical, legal and social aspects in the cooperation between Europe and China in Personalised Medicine. The policy brief is the result of the expertise by the Ethical, Legal and Societal Aspect (ELSA) Task Force that founded the project in 2023. It is also based on a workshop and a delegation visit to China where discussions were held with other experts on this topic. The insights gained from these activities are to be seen as recommendations for both policy and science. The document addresses three topics: 1.) Why is ELSA important for development and implementation of PM? 2.) Legal and regulatory aspects: the health data perspective and 3.) Ethical and societal perspectives. You can download the ELSA Policy Brief here: [Sino-EU PerMed ELSA Policy Brief](#)

The ELSA Policy Brief is based on the recommendations of the Sino-EU Projects' first Policy Brief on Science and Technology, which we published in 2022 on the basis of our stakeholder meeting. This policy brief on S&T can be found here: [Sino-EU PerMed S&T Policy Brief](#). The document addresses three topics: 1.) PM landscape in EU and China, 2.) Traditional Chinese Medicine in PM and 3.) Data sharing. For each topic the barriers and needs are identified and corresponding recommendations are provided.

In the process of drafting the ELSA policy brief, we have realised that the research stakeholders are very interested in joint cooperation between Germany and Korea. However, the framework conditions for this cooperation are becoming increasingly complex, so that a single scientist can no longer manage to navigate through this web of laws and measures on their own. Furthermore, still improvement is need to support the interaction between the different Chinese and European stakeholder from the field if academics, clinicians, decision makers, industry, and societal partners like e.g., patient organisations.

SINO-EU PerMed has been granted for funding through the current EU Framework Programme for Research and Innovation 'Horizon 2020' under grant agreement no 874556.